New York, NY -- (SBWIRE) -- 01/16/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Athersys, Inc (NASDAQ:ATHX), Infinera Corp (NASDAQ:INFN), Antares Pharma Inc (NASDAQ:ATRS), Alpine Total Dynamic Dividend Fund (NYSE:AOD)
Athersys, Inc (NASDAQ:ATHX) showed a volume of 1.45 million shares by the end of last trade whereas the average volume of the stock remained 2.20 million shares. The stock opened the session at $3.90 but then moved to $3.96. At that price, the stock showed a positive performance of 2.06%. Athersys Inc. is a biopharmaceutical company engaged in the field of regenerative medicine. During the year ended December 31, 2011 the Company is developing its platform product, MultiStem, a allogeneic stem cell product that has been evaluated in two completed Phase I clinical trials and as of December 31, 2011, is being evaluated in two ongoing Phase II clinical trials.
Will ATHX Continue To Move Higher? Find Out Here
Infinera Corp (NASDAQ:INFN) opened the session at $9.05 and closed the session at $9.13. The stock showed a positive performance of 1.00% in previous trading session. Traded with volume of 1.44 million shares in the prior session and the average volume of the stock remained 1.37 million shares. Infinera Corporation (Infinera) provides optical networking equipment, software and services to communications service providers, Internet content providers, cable operators and subsea network operators (collectively, Service Providers) across the globe. As of December 29, 2012, 111 Service Providers have selected Infinera’s optical architecture platform to efficiently grow and manage their optical networks. Infinera manufactures commercially-deployed, large-scale photonic integrated circuits (PICs).
For How Long INFN will fight for Profitability? Read This Trend Analysis report
Antares Pharma Inc (NASDAQ:ATRS) opened the session at $5.00 and closed the session at $4.95. The stock showed a positive performance of 0.41% in previous trading session. Traded with volume of 1.44million shares in the prior session and the average volume of the stock remained 1.42 million shares. The beta of the stock remained 0.14. Antares Pharma, Inc. (Antares) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products. The Company’s subcutaneous and intramuscular injection technology platforms include Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors.
Why Should Investors Buy ATRS After The Recent Gain? Just Go Here and Find Out
Alpine Total Dynamic Dividend Fund (NYSE:AOD) the stock advanced 0.47% and finished the session at $4.26. Traded with volume of 1.43 million shares in the prior session and the average volume of the stock remained 1.29 million shares. The beta of the stock remained 1.22. Alpine Total Dynamic Dividend Fund (the Fund) is a diversified, closed-end management investment company. The Fund’s investment objective is to seek high current dividend income. The Fund also focuses on long-term growth of capital as a secondary investment objective. It invests in various sectors, including consumer discretionary, industrials, energy, information technology, materials, consumer staples, healthcare, financials, utilities and telecommunication services.
Will AOD Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)